Esthesioneuroblastoma: 38 years of experience in an oncological center
Abstract
Background: Esthesioneuroblastoma (ENB) is an uncommon malignant sinonasal tumor. There are few data regarding ENB management, namely its treatment. We review our institute’s experience in the treatment of ENB and evaluate survival outcomes.
Materials and methods: Retrospective study of patients with ENB treated between 1984–2022. A total of 20 patients were identified, 13 men and 7 women, aged between 20 and 76 years.
Results: Eleven patients were stage C of the modified Kadish staging system at initial presentation, 7 stage B, 1 stage A and 1 stage D. Seventeen patients underwent surgery alone or combined with adjuvant treatment (radiotherapy or chemoradiotherapy). The majority of the patients (71.4%) treated with surgery alone were stage B, whereas most of the patients (63.6%) that underwent surgery combined with adjuvant treatment were stage C. Five of the 7 patients treated with surgery alone had a locoregional recurrence. Two of the 10 patients treated with surgery followed by adjuvant treatment had relapsed, locoregionally and at a distance, respectively. One patient was treated with chemotherapy and 2 patients were treated with chemoradiotherapy and neoadjuvant chemotherapy followed by chemoradiotherapy, respectively. The recurrence and persistence rates were 35% and 15%, respectively. The median time from the end of the first treatment to recurrence was 20.9 months. Two- and 5-year overall survival rates were 83.9% and 77.9%; while progression-free survival rates were 76.7% and 61.0%, respectively.
Conclusions: Sixty percent of patients were treated with a multimodal approach, which appeared to be a favorable strategy for the majority of patients.
Keywords: esthesioneuroblastomamultimodalchemotherapyradiotherapysurgery
References
- Broich G, Pagliari A, Ottaviani F. Esthesioneuroblastoma: a general review of the cases published since the discovery of the tumour in 1924. Anticancer Res. 1997; 17(4A): 2683–2706.
- Fiani B, Quadri SA, Cathel A, et al. Esthesioneuroblastoma: A Comprehensive Review of Diagnosis, Management, and Current Treatment Options. World Neurosurg. 2019; 126: 194–211.
- Toader C, Stroi M, Kozma A, et al. Esthesioneuroblastoma: the complete picture - case report and review of the literature. Rom J Morphol Embryol. 2018; 59(4): 1211–1218.
- Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma — A clinical analysis of 17 cases. Cancer. 1976; 37(3): 1571–1576, doi: 10.1002/1097-0142(197603)37:3<1571::aid-cncr2820370347>3.0.co;2-l.
- Morita A, Ebersold MJ, Olsen KD, et al. Esthesioneuroblastoma: prognosis and management. Neurosurgery. 1993; 32(5): 706–14; discussion 714.
- American Joint Committee on Cancer. AJCC Cancer Staging Manual. AJCC Cancer Staging Form Supplement. 8th ed . AJCC , Chicago 2018: 46–51.
- Costa S, Soares A, Vieira C. Esthesioneuroblastoma: a brief review of literature in the context of a case report. Rev Portug Oncol. 2022; 5(1): 26–29.
- Cunha ML, Oliveira RR, Césaro D, et al. Esthesioneuroblastoma: case reports and literature review. Brazi Neurosur. 2015; 34(2): 153–156.
- Alami Z, Farhane FZ, Bouziane A, et al. Management of Esthesioneuroblastoma: A Retrospective Study of 6 Cases and Literature Review. Case Rep Oncol. 2022; 15(1): 176–186.
- Bachar G, Goldstein DP, Shah M, et al. Esthesioneuroblastoma: The Princess Margaret Hospital experience. Head Neck. 2008; 30(12): 1607–1614.
- Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol. 2001; 2(11): 683–690.
- Dias FL, Sa GM, Lima RA, et al. Patterns of failure and outcome in esthesioneuroblastoma. Arch Otolaryngol Head Neck Surg. 2003; 129(11): 1186–1192.
- Eich HT, Hero B, Staar S, et al. Multimodality therapy including radiotherapy and chemotherapy improves event-free survival in stage C esthesioneuroblastoma. Strahlenther Onkol. 2003; 179(4): 233–240.
- Xiong Le, Zeng XL, Guo CK, et al. Optimal treatment and prognostic factors for esthesioneuroblastoma: retrospective analysis of 187 Chinese patients. BMC Cancer. 2017; 17(1): 254.
- Pickuth D, Heywang-Köbrunner SH, Spielmann RP. Computed tomography and magnetic resonance imaging features of olfactory neuroblastoma: an analysis of 22 cases. Clin Otolaryngol Allied Sci. 1999; 24(5): 457–461.
- Bak M, Wein RO. Esthesioneuroblastoma: a contemporary review of diagnosis and management. Hematol Oncol Clin North Am. 2012; 26(6): 1185–1207.
- Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology and genetics of head and neck tumours. World Health Organization Classification of tumours. IARC Press, Lyon 2005: 66–70.
- Jethanamest D, Morris LG, Sikora AG, et al. Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors. Arch Otolaryngol Head Neck Surg. 2007; 133(3): 276–280.
- Marinelli JP, Janus JR, Van Gompel JJ, et al. Esthesioneuroblastoma with distant metastases: Systematic review & meta-analysis. Head Neck. 2018; 40(10): 2295–2303.
- Platek ME, Merzianu M, Mashtare TL, et al. Improved survival following surgery and radiation therapy for olfactory neuroblastoma: analysis of the SEER database. Radiat Oncol. 2011; 6: 41.
- Tosoni A, Di Nunno V, Gatto L, et al. Olfactory neuroblastoma: diagnosis, management, and current treatment options. Front Oncol. 2023; 13: 1242453.
- Foote RL, Morita A, Ebersold MJ, et al. Esthesioneuroblastoma: the role of adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 1993; 27(4): 835–842.
- Mishima Y, Nagasaki E, Terui Y, et al. Combination chemotherapy (cyclophosphamide, doxorubicin, and vincristine with continuous-infusion cisplatin and etoposide) and radiotherapy with stem cell support can be beneficial for adolescents and adults with estheisoneuroblastoma. Cancer. 2004; 101(6): 1437–1444.
- Bhattacharyya N, Thornton AF, Joseph MP, et al. Successful treatment of esthesioneuroblastoma and neuroendocrine carcinoma with combined chemotherapy and proton radiation. Results in 9 cases. Arch Otolaryngol Head Neck Surg. 1997; 123(1): 34–40.
- Patil VM, Joshi A, Noronha V, et al. Neoadjuvant Chemotherapy in Locally Advanced and Borderline Resectable Nonsquamous Sinonasal Tumors (Esthesioneuroblastoma and Sinonasal Tumor with Neuroendocrine Differentiation). Int J Surg Oncol. 2016; 2016: 6923730.
- Goshtasbi K, Abiri A, Abouzari M, et al. Hyams grading as a predictor of metastasis and overall survival in esthesioneuroblastoma: a meta-analysis. Int Forum Allergy Rhinol. 2019; 9(9): 1054–1062.
- Malouf GG, Casiraghi O, Deutsch E, et al. Low- and high-grade esthesioneuroblastomas display a distinct natural history and outcome. Eur J Cancer. 2013; 49(6): 1324–1334.
- Zeng Q, Tian Y, He Y, et al. Long-Term Survival Outcomes and Treatment Experience of 64 Patients With Esthesioneuroblastoma. Front Oncol. 2021; 11: 624960.
- Song X, Wang J, Wang S, et al. Prognostic factors and outcomes of multimodality treatment in olfactory neuroblastoma. Oral Oncol. 2020; 103: 104618.
- Ozsahin M, Gruber G, Olszyk O, et al. Outcome and prognostic factors in olfactory neuroblastoma: a rare cancer network study. Int J Radiat Oncol Biol Phys. 2010; 78(4): 992–997.
- Harvey RJ, Nalavenkata S, Sacks R, et al. Survival outcomes for stage-matched endoscopic and open resection of olfactory neuroblastoma. Head Neck. 2017; 39(12): 2425–2432.
- Shaaban SG, Caicedo-Granados E, Wilke C. Clinical Outcomes and Patterns of Failure in Esthesioneuroblatoma: A Single Institutional Experience. Indian J Otolaryngol Head Neck Surg. 2023; 75(1): 67–73.